Mr. Joshua Bartch
MYDECINE INNOVATIONS GROUP ANNOUNCES
ISSUANCE OF WARRANTS
Mydecine Innovations Group Inc. has issued an aggregate 35,737,460 share purchase warrants of the company to certain shareholders who have agreed to extend the resale restrictions on their common shares for an additional 120 days as previously announced on Sept. 3, 2020. The warrants were issued to the shareholders in consideration for entering into their lock-up agreements.
Every four warrants will entitle the holder thereof to purchase one common share of the company at a price of 30 cents per warrant share until Sept. 28, 2021.
About Mydecine Innovations Group Inc.
Mydecine Innovations Group is a publicly traded life science parent company dedicated to the development and production of adaptive pathway medicine, natural health products and digital health solutions stemming from fungi. Mydecine's experienced cross-functional teams have the dynamic capabilities to oversee all areas of medicine development, including synthesis, genetic research, import/export, delivery system development and clinical trial execution, through to product commercialization and distribution. By leveraging strategic partnerships with scientific, medical, military and clinical organizations, Mydecine is positioned at the forefront of psychedelic medicine naturally derived from fungi, therapeutic solutions and fungtional mushroom vitality products. Its portfolio of unified companies, including Mydecine Health Sciences, Mindleap Health and NeuroPharm, focus on providing innovative and effective options that can provide millions of people with a healthier quality of life.
We seek Safe Harbor.
© 2020 Canjex Publishing Ltd. All rights reserved.